ArriVent doses first patient in Phase 1 trial of ARR-002 dual-target ADC for ovarian, endometrial cancer

ArriVent Biopharma has dosed the first patient in a US Phase 1 trial of ARR-002, a dual-target antibody-drug conjugate for ovarian and endometrial cancer. This milestone marks the study's initiation rather than providing efficacy or safety data. ARR-002 targets two tumor markers to improve delivery in mixed-expression tumors. Shanghai Allist holds exclusive rights for Greater China, while ArriVent retains rights elsewhere.

ArriVent dosed the first patient in a US Phase 1 trial of ARR-002 for ovarian and endometrial cancer. * No clinical results have been presented yet; the update marks the study’s start rather than an efficacy or safety readout. * ARR-002 is designed to target two tumor markers to improve drug delivery across tumors with mixed target expression. * Shanghai Allist holds an exclusive license to develop and commercialize ARR-002 in Greater China; ArriVent retained rights elsewhere. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610121601PRIMZONEFULLFEED9844005) on October 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)